Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.

Shimizu T, LoRusso PM, Papadopoulos KP, Patnaik A, Beeram M, Smith LS, Rasco DW, Mays TA, Chambers G, Ma A, Wang J, Laliberte R, Voi M, Tolcher AW.

Clin Cancer Res. 2014 Oct 1;20(19):5032-40. doi: 10.1158/1078-0432.CCR-14-0570. Epub 2014 Aug 8.

2.

Bumps in the journey toward a new care delivery model.

Shendell-Falik N, Ide P, Mohr BJ, Laliberte RA, de Guerre DW.

Nurs Adm Q. 2012 Jul-Sep;36(3):243-52. doi: 10.1097/NAQ.0b013e318258c4f4.

PMID:
22677965
3.

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

Morse MA, Bradley DA, Keler T, Laliberte RJ, Green JA, Davis TA, Inman BA.

Expert Rev Vaccines. 2011 Jun;10(6):733-42. doi: 10.1586/erv.11.20. Review.

PMID:
21692696
4.

A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.

Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, Laliberté RJ, Ryan JL, Zonno K, Rook AH.

J Am Acad Dermatol. 2006 Nov;55(5):807-13. Epub 2006 Sep 8.

PMID:
17052486
5.

Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development.

McClure KF, Letavic MA, Kalgutkar AS, Gabel CA, Audoly L, Barberia JT, Braganza JF, Carter D, Carty TJ, Cortina SR, Dombroski MA, Donahue KM, Elliott NC, Gibbons CP, Jordan CK, Kuperman AV, Labasi JM, Laliberte RE, McCoy JM, Naiman BM, Nelson KL, Nguyen HT, Peese KM, Sweeney FJ, Taylor TJ, Trebino CE, Abramov YA, Laird ER, Volberg WA, Zhou J, Bach J, Lombardo F.

Bioorg Med Chem Lett. 2006 Aug 15;16(16):4339-44. Epub 2006 Jun 12.

PMID:
16759861
6.

Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder.

Weiss GR, O'Donnell MA, Loughlin K, Zonno K, Laliberte RJ, Sherman ML.

J Immunother. 2003 Jul-Aug;26(4):343-8.

PMID:
12843796
7.

Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing.

Laliberte RE, Perregaux DG, Hoth LR, Rosner PJ, Jordan CK, Peese KM, Eggler JF, Dombroski MA, Geoghegan KF, Gabel CA.

J Biol Chem. 2003 May 9;278(19):16567-78. Epub 2003 Mar 6.

8.

The role for interleukin-12 therapy of cutaneous T cell lymphoma.

Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, Foss F, Shapiro M, Kuzel TM, Olsen EA, Vonderheid EC, Laliberte R, Sherman ML.

Ann N Y Acad Sci. 2001 Sep;941:177-84.

PMID:
11594571
9.

Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors.

Perregaux DG, McNiff P, Laliberte R, Hawryluk N, Peurano H, Stam E, Eggler J, Griffiths R, Dombroski MA, Gabel CA.

J Pharmacol Exp Ther. 2001 Oct;299(1):187-97.

10.

Decreased capacity of asthmatic bronchial fibroblasts to degrade collagen.

Laliberté R, Rouabhia M, Bossé M, Chakir J.

Matrix Biol. 2001 Jan;19(8):743-53.

PMID:
11223333
11.

ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood.

Perregaux DG, McNiff P, Laliberte R, Conklyn M, Gabel CA.

J Immunol. 2000 Oct 15;165(8):4615-23.

12.

ATP treatment of human monocytes promotes caspase-1 maturation and externalization.

Laliberte RE, Eggler J, Gabel CA.

J Biol Chem. 1999 Dec 24;274(52):36944-51.

13.

Human monocyte ATP-induced IL-1 beta posttranslational processing is a dynamic process dependent on in vitro growth conditions.

Laliberte RE, Perregaux DG, McNiff P, Gabel CA.

J Leukoc Biol. 1997 Aug;62(2):227-39.

PMID:
9261337
14.

Human monocyte interleukin-1beta posttranslational processing. Evidence of a volume-regulated response.

Perregaux DG, Laliberte RE, Gabel CA.

J Biol Chem. 1996 Nov 22;271(47):29830-8.

15.

Lower airways remodeling in nonasthmatic subjects with allergic rhinitis.

Chakir J, Laviolette M, Boutet M, Laliberté R, Dubé J, Boulet LP.

Lab Invest. 1996 Nov;75(5):735-44.

PMID:
8941218
16.

Inhibition of cytokine activation processes in vitro by tenidap, a novel anti-inflammatory agent.

McNiff PA, Laliberte RE, Svensson L, Pazoles CJ, Gabel CA.

Cytokine. 1995 Feb;7(2):196-208.

PMID:
7780040
17.
18.

Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention.

Crane P, Laliberté R, Heminway S, Thoolen M, Orlandi C.

Eur J Nucl Med. 1993 Jan;20(1):20-5.

PMID:
7678396
19.

Meeting report. The biochemistry and pharmacology of interleukins-1 and -6.

Carty TJ, Laliberte RE.

Agents Actions. 1989 Mar;26(3-4):391-3. No abstract available.

PMID:
2525315
20.

Effectiveness of mandibular infiltration in children using the local anesthetic Ultracaine (articaine hydrochloride).

Dudkiewicz A, Schwartz S, Laliberté R.

J Can Dent Assoc. 1987 Jan;53(1):29-31. No abstract available.

PMID:
3545399
21.

[Ultracaine in conventional operative dentistry].

Lemay H, Albert G, Hélie P, Dufour L, Gagnon P, Payant L, Laliberté R.

J Can Dent Assoc. 1984 Sep;50(9):703-8. French. No abstract available.

PMID:
6386124
22.

Nomifensine in the treatment of depressed geriatric patients.

Goldstein SE, Birnbom F, Laliberte R.

J Clin Psychiatry. 1982 Jul;43(7):287-9.

PMID:
7045090
23.

Procurement of hepatocytes for a hybrid artificial liver.

Jauregui HO, Hayner N, Laliberte R, Lipski M, McMillan P, Galletti PM.

Trans Am Soc Artif Intern Organs. 1979;25:487-92. No abstract available.

PMID:
392883
24.
25.

The influence of fasting on the disposition of warfarin in rats.

Laliberte R, Chakrabarti S, Brodeur J.

J Pharmacol Exp Ther. 1977 Jan;200(1):44-51.

PMID:
833761
26.

Influence of long-chain free fatty acids on the binding of waraarin to bovine serum albumin.

Chakrabarti S, Laliberté R, Brodeur J.

Biochem Pharmacol. 1976 Nov 15;25(22):2515-21. No abstract available.

PMID:
985573
27.

Inhibition of vitamin K epoxidase by two non-coumarin anticoagulants.

Willingham AK, Laliberte RE, Bell RG, Matschiner JT.

Biochem Pharmacol. 1976 May 1;25(9):1063-6. No abstract available.

PMID:
1267851
28.

The influence of fasting and stress on the response of rats to warfarin.

Laliberté R, Chakrabarti S, Brodeur J.

J Pharmacol Exp Ther. 1976 Jan;196(1):194-203.

PMID:
54416
29.
30.

Oxidation of furans. 2. Synthesis and biological properties of 6-hydroxy-2H-pyran-3(6H)-ones and derivatives.

Laliberté R, Médawar G, Lefebvre Y.

J Med Chem. 1973 Oct;16(10):1084-9. No abstract available.

PMID:
4201420
31.

[The nurse and rehabilitation].

Laliberté RD.

Bull Infirm Cathol Can. 1967 May-Jun;34(3):119-24. French. No abstract available.

PMID:
5182902
32.

[Health services in our hospitals].

Laliberté RD.

Bull Infirm Cathol Can. 1966 May-Jun;33(3):124-34. French. No abstract available.

PMID:
5177355
33.

[Preliminary studies of the effects of substituted 2,4-diaminobutyric acids in the rat].

LALIBERTE R, BERLINGUET L.

Laval Med. 1962 Nov;33:675-9. French. No abstract available.

PMID:
13928187

Supplemental Content

Loading ...
Support Center